Shanghai Junshi Biosciences Co (688180) Fair Value & Analysis
Healthcare · CN · Market cap 31.0B CNY
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 7 days ago
Share price −13.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥29.39 – ¥49.57 · fair‑value band ¥26.58 – ¥44.31 · the ¥30.15 price screens below the ¥35.45 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shanghai Junshi Biosciences Co (688180) currently trades at ¥30.15, while our model-based Fair Value estimate is ¥35.45 — implying the stock looks roughly 17.6% undervalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Shanghai Junshi Biosciences Co generated revenue of 2.7B CNY at a net margin of -24.3%. Revenue grew 45.1% year over year. It earns a return on equity of -13.5%. Net debt stands at 1.5B CNY. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Junshi Biosciences Co reported revenue of ¥2.5B in FY2025 versus ¥4.0B in FY2021, a compound −11.2%/yr. Reported net income was −¥875M in FY2025.
Is 688180 fairly valued? → Check now
Recent news
- Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Re
- Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
- Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR
- Shanghai Junshi Biosciences (SEHK:1877) Valuation Check After Mixed One Year And Three Year Returns
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai Junshi Biosciences Co (688180) undervalued?
What is the fair value of 688180?
What is the quality score of 688180?
What is the revenue of Shanghai Junshi Biosciences Co (688180)?
What is the net profit margin of 688180?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.